On the basis of the synergism of topoisomerase (Top) and histone deacetylase (HDAC)
inhibitors in antitumor therapy, a series of novel Top/HDAC dual inhibitors were designed …

On the basis of synergistic effect between topoisomerase (Top) and histone deacetylase
(HDAC) inhibitors, a series of novel evodiamine-based Top/HDAC dual inhibitors were …

A great challenge in multi-targeting drug discovery is to identify drug-like lead compounds
with therapeutic advantages over single target inhibitors and drug combinations. Inspired by …

Designing multitarget drugs remains a significant challenge in current antitumor drug
discovery. Because of the synergistic effect between topoisomerase and HDAC inhibitors …

Multitarget inhibitors design has generated great interest in cancer treatment. Based on the
synergistic effects of topoisomerase and histone deacetylase inhibitors, we designed and …

Aim: The previously reported dual histone deacetylase type II (HDAC II)/topoisomerase type
I (Topo I) inhibitors suffer pharmacokinetic limitations because of their huge molecular …

Due to the multimodal character of cancer, inhibition of two targets simultaneously by a
single molecule is a beneficial and effective approach against cancer. Histone deacetylase …

Histone deacetylases (HDACs) play an important role in regulating target gene expression.
They have been highlighted as a novel category of anticancer targets, and their inhibition …

Strategies to ameliorate the flaws of current chemotherapeutic agents, while maintaining
potent anticancer activity, are of particular interest. Agents which can modulate multiple …

Topoisomerase has been found extremely high level of expression in hepatocellular
carcinoma (HCC) and proven to promote the proliferation and survival of HCC. Cancer …